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This review attempts to provide an overview of the current knowledge of TRP proteins and their possible role in bladder function and disease.
At present, there are 28 transient receptor potential (TRP) channels (subdivided into 7 categories or families) which are involved in a number of
functions [G.A. Hicks, TRP channels as therapeutic targets: hot property, or time to cool down? Neurogastroenterology and Motility 18, (2006)
590–594., J.D. Levine, N. Alessandri-Haber, TRP channels: targets for the relief of pain, Biochimica et Biophysica Acta 1772, (2007) 989–
1003.]. Of those belonging to the group 1 subfamily, a number of TRPV, TRPM and TRPA proteins associated with osmoregulation, thermal,
chemical and mechanical signaling mechanisms have been shown to be expressed within the lower urinary tract. Though the biological role of
many of these channels in urinary bladder function still remains elusive, TRPV1 is by far the best characterized and is thought to be involved in a
number of bladder disorders [A. Szallasi, P.M. Blumberg, Vanilloid (Capsaicin) Receptors and Mechanisms, Pharmacological Reviews 51, (1999)
150–221., I. Nagy, P. Santha, G. Jansco, L. Urban, The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology, European
Journal of Pharmacology 500, (2004) 351–369.].
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TRPV1 previously known as the vanilloid receptor type 1
or the capsaicin receptor, is a ligand gated ion channel
activated by capsaicin, heat, acidosis and endogenous agonists
(such as anandamide, 12-hydroxyeicosatetranoic acid) [4–6].
Interest in TRP channel structure and function was stimulated
by early studies of the actions agents such as capsaicin and
resiniferatoxin (RTX) [1–3]. Capsaicin (first isolated from
chili peppers in 1919) became a ‘hot’ topic when it was found
to have specific binding sites in a number of tissues including
sensory nerves [7–9]. This culminated in the cloning of the
vanilloid receptor [5], identified by using capsaicin as a
ligand.
2. TRPV1 expression and function in the urinary bladder
Both the upper and lower urinary tract are densely innervated
by capsaicin-sensitive primary afferent neurons in a number of⁎ Tel.: +1 412 383 7368; fax: +1 412 648 7197.
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doi:10.1016/j.bbadis.2007.04.003species including man [7]. Early functional studies revealed that
capsaicin-sensitive C type bladder fibers play a role in mic-
turition [7,10]. It was shown that capsaicin sensitive nerves
exhibit both a sensory and also an “efferent” function which is
determined by release of peptides including tachykinins such as
substance P as well as other peptides such as calcitonin gene-
related peptide [3,11]. The sensory function includes the regu-
lation of the micturition threshold and the perception of pain
from the urinary bladder, while the efferent function controls
nerve excitability, smooth muscle contractility and plasma pro-
tein extravasation.
The expression of capsaicin-sensitive nerve fibers in the
lower urinary tract was first demonstrated following binding
of radiolabeled resiniferatoxin in the bladder and urethra of the
rat [7,9]. Subsequently the use of antibodies to TRPV1
revealed TRPV1-immunoreactive nerve fibers in subpopula-
tions of bladder nerves including unmyelinated (C-fiber)
nerves that detect bladder distension or the presence of irritant
chemicals [12–14]. These fibers could be localized near and
within the bladder mucosa, in addition to close proximity to
blood vessels and smooth muscle cells [12,15]. Within the
muscular layer, these nerve fibers appear close to the smooth
Fig. 1. TRPV1 is detected in urothelial cells of the rat urinary bladder. Left panel, confocal image of urinary bladder urothelium reveals TRPV1 (cy3, red) and
cytokeratin (FITC, green) expression. Arrow indicates apical cells within the field from a single plane of focus. Right panel, enlarged image of basal cells depicting
TRPV1 (cy3, red) and cytokeratin (FITC, green) in urothelium. Scale bar: left, 15 μm; right, 5 μm.
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anatomical relations suggest that TRPV1 bladder nerves may
potentially modulate urothelial function and/or smooth muscle
contractility via the release of sensory peptides contained in
TRPV1 bladder fibers.
In the urinary bladder, one of the more remarkable findings
is that TRPV1 is not only expressed by afferent nerves that
form close contact with the bladder epithelium but also in non-
neuronal cells including urothelial cells and myofibroblasts
(Fig. 1) (Table 1) [12,13]. The urothelium is a multilayered
structure which has been shown to express a number of
receptors/ion channels similar to that of mechanoreceptor and
nociceptor neurons [16–18].Urothelial cells may be actively
engaged in communicating with bladder nerves, adjacent
urothelial cells, smooth muscle or even cells of the immune
systems. For example, urothelial cells can release a variety of
products, such as ATP, prostaglandins and nitric oxide, which
can alter excitability of bladder afferent nerves [16]. In turn,
nociceptive afferent activation releases a number of factors,
such as substance P that can activate urothelial cells. These
data raise the possibility of bidirectional chemical communi-
cation between urothelium and bladder nerves. TRPV1 could
play a role in the communication because activation of
urothelial TRPV1 receptors with capsaicin or resiniferatoxin
increases intracellular calcium and evokes transmitter (nitric
oxide, NO or ATP) release in cultured cells [12,13]. As noted
in sensory neurons, these responses are enhanced by low pH,Table 1
Comparison of TRP channel properties in urinary bladder urothelial cells, interstitia
TRPV1 TRPV2 TRPV3
Urinary bladder
urothelium
Expression;
Function [12,13,15,16,64]
Expression [12,16] Not shown
Urinary bladder
afferent nerves
Expression;
Function [3,5,8–10,12–15]
Not shown Not shown
Urinary bladder
interstitial cells
Expression [19] Not shown Not shown
Skin keratinocytes Expression; Function [73] Not shown Expression;
Function [73,blocked by TRPV1 antagonists and eliminated in TRPV1 null
mice [13]. In neurons, TRPV1 is thought to integrate/amplify
the response to various stimuli and to play an essential role in
the development of inflammation-induced hyperalgesia. Thus,
it seems likely that urothelial-TRPV1 might participate in a
similar manner, in the detection of irritant stimuli following
bladder inflammation or infection.
Cultured urothelial cells from TRPV1 null mice also exhibit
a reduction in stretch-evoked and hypotonic-evoked ATP re-
lease and stretch-evoked increase in membrane capacitance
[13]. In addition, TRPV1 knockout mice have a higher
frequency of low-amplitude, non-voiding bladder contractions
suggesting the possibility of a small but ongoing role for
TRPV1 in normal micturition [13]. This is also accompanied
by a reduction in bladder distension-evoked c-fos expression in
the spinal cord and reflex voiding. These relatively benign
changes may result from TRPV1 expression not only in
afferent nerves that form close contacts with bladder epithelial
(urothelial) cells but also in urothelial cells themselves. These
findings demonstrate that the functional significance of TRPV1
in the bladder extends beyond pain sensation to include
participation in normal voiding function, and is essential for
mechanically evoked purinergic signaling by the urothelium.
TRPV1 immunoreactivity has also been identified in a
population of cells located in the sub-urothelial space [19].
These cells have morphological characteristics of myofibro-
blasts and stain intensively for vimentin and the gap junctionl cells, afferent nerves and skin keratinocytes
TRPV4 TRPM8 TRPA1
Expression;
Function [16,47,48]
Expression;
Function [16,58]
Expression;
Function [16]
Function [16,47,48] Function [50,52,53,54,56,57] Function
[50,52–54,56,57,61]
Not shown Not shown Not shown
74]
Expression;
Function [73]
Not shown Not shown
Fig. 2. Cystometrograms (CMGs) in anesthetized CNS-intact and unanesthe-
tized chronic spinal rats recorded under isotonic conditions with the bladder
outlet open and the animals able to void. Top panel: CMG pattern with an
infusion rate of 0.052 ml/min in anesthetized CNS-intact rat. Middle panel:
CMG pattern (infusion rate 0.104 ml/min) in a chronic spinal rat before
capsaicin treatment. Note relatively small nonvoiding contractions occurring
during bladder filling and their amplitude progressively increasing with filling
(Premicturition contractions, PMC). Bottom panel: the same chronic spinal rat
after capsaicin (125 mg/kg s.c.) pretreatment 4 days before the CMG study. Note
the nonvoiding contractions were eliminated but the voiding contraction was not
altered. Vertical calibrations: intravesical pressure in cm H2O and horizontal
calibrations: time in min. Asterisks (⁎) indicate voiding.
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“myofibroblast” or “interstitial” type cells may function as
“pacemaker” cells in the bladder and have the capacity to
modulate bladder sensations [20–22]. This hypothesis is given
added support by the fact that many nerve fibers terminate on
these cells, thus providing a means to modulate the sensitivity
of bladder filling sensations. Understanding the mechanisms
contributing to and maintaining these types of cell–cell
interactions may provide important insight into development
of novel targets for clinical management of a number of
bladder disorders.
3. Role of TRP channels in bladder disorders
TRPV1 has attracted a lot of attention as an important player
in bladder diseases. TRPV1 knockout mice display differences
in the response to inflammation or injury as compared to their
wild-type counterparts. For example, TRPV1 knockout mice
do not develop bladder overactivity during acute bladder
inflammation, suggesting that TRPV1 is involved in bladder
hyperreflexia in inflammatory states [23,24]. In addition,
patients suffering from neurogenic detrusor overactivity exhibit
significant increases in the number of TRPV1-expressing
nerves as well as TRPV1 expression within the urothelium
[25,26]. These and other data which show a link between TRP
channel expression or sensitivity and disease symptoms
provide further support for a role of TRPV1 in the development
of visceral hyperalgesia in the bladder.
In pathological conditions such as inflammation or following
a spinal cord injury, increased reflex bladder contractions and
emptying are triggered by activation of capsaicin sensitive C
fibers. This emergence of a capsaicin-sensitive, C-fiber me-
diated spinal micturition reflex is thought to be due to reorga-
nization of synaptic connections in the spinal cord and changes
in the properties of the afferents [27,28]. Systemic administra-
tion of capsaicin is effective in animal models to block the
hyperreflexia associated with neurogenic bladder dysfunctions
following spinal cord injury (Fig. 2) [29–31]. This effect of
capsaicin is attributable to induction of a long lasting refractory
state in primary afferent neurons termed “capsaicin desensiti-
zation”. It is in this context that intravesical treatments with
vanilloid compounds have been demonstrated to be beneficial
in bladder disorders such as neurogenic bladder in patients with
multiple sclerosis or following a spinal cord injury or hyper-
sensitivity disorders such as interstitial cystitis (IC) [29,32–42].
Intravesical vanilloids have also been shown to dramatically
reduce the number of bladder sensory fibers immunoreactive for
TRPV1, substance P or CGRP in patients with painful bladder
symptoms [25,43]. This is due in part to the either a depletion of
afferent transmitters or degeneration of the peripheral nerve
endings in the wall of the urinary bladder.
Though there is evidence that intravesical vanilloid therapy is
successful, with a net effect to increase bladder capacity and to
diminish bladder urge sensations associated with these bladder
disorders [40], its use has been largely abandoned due to a high
incidence of patient discomfort, poor bioavailability in addition to
concerns about irreversible neurotoxicity. The use of resinifer-atoxin (RTX) was met with initial enthusiasm as this compound is
thought to exhibit an effect similar to capsaicin on bladder
afferents but with lower toxicity. In patients with neurogenic
detrusor overactivity exhibiting increased TRPV1 expression in
both bladder nerves and the urothelium, intravesical treatment
with RTX reduced TRPV1 immunoreactivity in both suburothe-
lial afferent nerve and urothelial cells [25,44]. In addition, RTX
has also been used in patients with IC [33,45].While initial results
with RTX were encouraging with improvements in bladder
capacity and patients tolerating RTX better than capsaicin,
analysis of clinical trial data revealed that RTX was ineffective
and additional studies would not be pursued.
4. Additional TRP channels
Much less is known about the involvement of other TRPs
in bladder function or disease. TRPV4 which is a nonselective
cation channel activated by a number of stimuli including heat,
shear stress, changes in osmolarity and lipid ligands is ex-
pressed in the urinary bladder [46–48]. A definitive role for
TRPV4 in bladder function has not been established.
However, in other systems, TRPV4 seems to play a role in
hypo-osmotic hyperalgesia and in the development of
neuropathic pain [49].
While little is known about the involvement of the cold-
sensing TRP channels (TRPM8 and TRPA1) in bladder func-
tion, the effects of cold temperatures on lower urinary tract
function has long been of interest [50,51]. The instillation of
cold solutions (known as the ice water test) elicits involuntary
detrusor contractions in patients with either chronic spinal cord
lesions or following bladder outlet obstruction [51–54]. This
reflex is believed to be mediated by activation of C-type afferent
882 L.A. Birder / Biochimica et Biophysica Acta 1772 (2007) 879–884fibers within the pelvic nerve sensitive to cold temperatures.
The finding that intravesical instillation of menthol facilitates
the bladder cooling reflex in both the cat and human suggests
that TRPM8, a cold- and menthol-sensing channel [55–57],
may be involved in triggering the reflex. In the urinary bladder,
TRPM8-positive immunoreactivity has been demonstrated
within bladder nerves as well as the urothelium [58]. Because
of the increased expression of TRPM8 in prostate cancer cells,
this channel may also function as a potential tumor marker with
utility in both the diagnosis and possible therapy for the treat-
ment of cancer [59,60].
TRPA1 (formerly named ANKTM1) has been characterized
as a thermoreceptor activated by noxious cold. Recent studies
have shown that this channel is localized in sensory nerves that
innervate the urinary bladder and mediates a contractile effect
on bladder smooth muscle, likely due to release of tachykinins
and cyclooxygenase metabolites [61]. The effect on smooth
muscle contractility of agents capable of stimulating TRPA1
was comparable in potency to capsaicin, supporting the specu-
lation that this channel may play a role in bladder function.
5. New directions for therapeutic treatments
The use of botulinum neurotoxin type A (BoNT/A) has been
successful in the treatment of lower urinary tract symptoms such
as frequency and urgency incontinence due to neurogenic or
idiopathic overactivity of detrusor smooth muscle [62]. The
mechanism of action was initially thought to involve blocking
the vesicular release of neurotransmitters from efferent nerves
resulting in reduced smooth muscle contractility. Because of
patient reports of dramatic reductions in the sensation of ur-
gency, it is now believed that the mechanism of action of this
toxin in the overactive bladder may be more complicated and
could involve modulation of purinergic or TRPV1-signaling
mechanisms in afferent pathways. It has also been shown that the
expression levels of TRPV1 may be regulated by nerve growth
factor (NGF). Thus, a decrease in NGF production by botulinum
toxin may in turn result in reduced TRPV1-mediated peptide
release and prolonged desensitization of bladder afferents [63].
In addition, the reduction in nerve staining of the purinergic
receptor P2X3 and TRPV1 after botulinum treatment may be due
to a reduction in NGF levels which in turn, could reduce puri-
nergic and/or TRP channel trafficking [64]. It is proposed that
the decreased levels of sensory receptors may contribute to the
clinical efficacy of BoNT/A in detrusor overactivity.
6. Complex regulation of TRP channels
TRP channels are complex not only because they are poly-
modal, i.e., respond to multiple external stimuli, but also be-
cause they are modulated by intracellular signaling
mechanisms such as protein kinase induced phosphorylation
and changes in intracellular Ca2+ concentration. In addition
homomeric and heteromeric interactions between different
TRP isoforms/splice variants and other accessory proteins
could influence TRP channel function [65,66]. Whether co-
assembly occurs between subunits belonging to TRPV1 andTRPV4 or TRPA1 is not presently known but would be one
explanation for the sensitivity of TRPV1 to mechanical stimuli.
Recent studies have also highlighted the complex effects of
TRP channel agonists such as menthol, camphor and
cinnamaldehyde on multiple temperature sensitive TRPs [67].
The activation and inhibition of multiple TRP channels by
these and other agents may occur via a direct effect on the
channel or indirect, via modification of membrane structure,
binding to other receptors or activation of second messengers.
Though it is still unclear as to how one TRP channel may have
multiple functions or how various TRP channel proteins
interact within a cell, these channels will undoubtedly continue
to be a major focus of research into the mechanisms underlying
diseases of the lower urinary tract.
7. Conclusions
The vast numbers of TRP channels, their broad expression
patterns and redundancy of receptor expression in both neuronal
and non-neuronal cells, the ability to respond to a number of
stimulus modalities and the lack of specific antagonists have
made their study in bladder function difficult. Intravesical in-
stillation of vanilloids (capsaicin or resiniferatoxin, RTX) has
demonstrated improvement in a number of urodynamic param-
eters in patients with detrusor overactivity and patients with
hypersensitivity disorders such as IC, presumably by desensi-
tizing bladder nerves. However, the high incidence of side
effects in patients following intravesical administration with
capsaicin has made this treatment a “double-edged sword” thus
providing concerns regarding the selectivity of TRPV1 agonists
for clinical use. In addition, the diverse mechanisms underlying
many bladder disorders have promoted interest in the
identification of small molecule TRP antagonists (in particular
TRPV1) for the treatment of many of these conditions.
There is particular interest in TRPV1 due to the number
of endogenous ligands known to accumulate in diseased
tissue that could activate this channel. Besides moderate heat
and low pH, TRPV1 can also be activated by the
cannabinoid receptor ligand anandamide, the eicosanoids
12-(S)-HPETE, 15-(S)-HPETE, 5-(S)-HETE, and leukotriene
B2, endogenous lipids and the so-called endovanilloids such
as the endogenous compounds arachidonylethanolamide and 2-
arachidonoyl-glycerol [6,68,69]. In addition to these endogenous
activators which are generated during inflammation, TRPV1
channel activation can also be sensitized by phosphorylation such
as by protein kinase C (PKC), which itself can be activated
through a number of G protein coupled receptor pathways
including bradykinin, ATP, acetylcholine or substance P, whose
levels may be augmented during inflammation [70,71]. In
support of this idea are demonstrations of abnormal TRPV1
responses in a cat model for IC [72]. In this model it was reported
that afferent neurons exhibit abnormal capsaicin responses due in
part to enhanced endogenous activity of PKC. Thus, it can be
imagined that in the near future new antagonist based therapies
that are selective for abnormal TRPV1 receptors sparing those
with physiological functions may be used in the treatment in a
number of bladder disorders.
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